Physician

Internal Medicine

Dr. David P. Schenkein, MD

Doctor David P. Schenkein, MD is an expert in the field of Internal Medicine. He graduated from State University of New York Upstate Medical University. David P. Schenkein is a published physician. He published 22 publications, including: 'O11.2AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model.'

Publications

O11.2AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model.
IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition.
Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate.
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Reevaluating the Accelerated Approval Process for Oncology Drugs.
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation.
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Cancer-Associated Isocitrate Dehydrogenase Mutations.
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping.
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Preclinical data with bortezomib in lung cancer.
Use of proteasome inhibition in the treatment of lung cancer.
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 51...
Targeted therapies for cancer 2004.
Pharmacogenomics.
Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
A phase 2 study of bortezomib in relapsed, refractory myeloma.

Schools

Upstate Medical University College of Health Professions

Doctors Specialties

Hematology
Medical Oncology
Oncology
Internal Medicine

Accepted Insurances

Education

Tufts Medical Center
State University of New York Upstate Medical University

Hospital

Tufts Medical Center

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Daniel E. Morganstern, MD This Doctor is OpenDoctor Recommended.
	Dr. Daria V. Babushok, MD This Doctor is OpenDoctor Recommended.
	Dr. Hsiu-Hung Wang, MD
	Dr. Ravi I. Thadhani, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Aaron D. Goldberg, MD This Doctor is OpenDoctor Recommended.
	Dr. Gerald W. Hsu, MD
	Dr. Anna F. Farago, MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher Lee Carpenter, MD This Doctor is OpenDoctor Recommended.
	Dr. William C. Aird, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Eddy J. Chen, MD This Doctor is OpenDoctor Recommended.
	Dr. Nicole G. Chau, MD This Doctor is OpenDoctor Recommended.
	Dr. Prudence Lam, MD
	Dr. Yi-Bin A. Chen, MD This Doctor is OpenDoctor Recommended.
	Dr. Beverly Moy, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Eugene Chan, MD
	Dr. Brenton B. Fargnoli, MD
	Dr. Joel G. Caslowitz, MD This Doctor is OpenDoctor Recommended.
	Dr. Monica Campo, MD
	Dr. David A. Drew, MD This Doctor is OpenDoctor Recommended.